332013-42-0

Basic information

• Product Name: 2-METHYLCARBAMOYLISONICOTINIC ACID ETHYL ESTER
• Synonyms: ETHYL 2-[(METHYLAMINO)CARBONYL]ISONICOTINATE;2-METHYLCARBAMOYLISONICOTINIC ACID ETHYL ESTER;2-[(METHYLAMINO)CARBONYL]-PYRIDINE-4-CARBOXYLIC ACID ETHYL ESTER;2-[(Methylamino)carbonyl]-pyridine-4-carboxylic acid ethylester;4-Pyridinecarboxylic acid, 2-[(methylamino)carbonyl]-, ethyl ester
• CAS NO: 332013-42-0
• Molecular Formula: C₁₀H₁₂N₂O₃
• Molecular Weight: 208.21
• Mol File: 332013-42-0.mol

Chemical Properties

• Boiling Point: 371.4 °C at 760 mmHg
• Flash Point: 178.4 °C
• Appearance: /
• Density: 1.173 g/cm³
• Vapor Pressure: 1.03E-05mmHg at 25°C
• Refractive Index: 1.525
• CAS DataBase Reference: 2-METHYLCARBAMOYLISONICOTINIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-METHYLCARBAMOYLISONICOTINIC ACID ETHYL ESTER(332013-42-0)
• EPA Substance Registry System: 2-METHYLCARBAMOYLISONICOTINIC ACID ETHYL ESTER(332013-42-0)

Safety Data

• Hazardous Substances Data: 332013-42-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Applications:
2-METHYLCARBAMOYLISONICOTINIC ACID ETHYL ESTER is used as an intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and properties make it a valuable component in the development of new drugs and treatments for a range of medical conditions.
Used in Research:
2-METHYLCARBAMOYLISONICOTINIC ACID ETHYL ESTER is used as a research compound in the fields of chemistry and pharmacology. Its unique properties and potential applications make it a valuable tool for studying the mechanisms of action and potential therapeutic uses of related compounds.
Used in Drug Development:
2-METHYLCARBAMOYLISONICOTINIC ACID ETHYL ESTER is used in the development of new drugs and treatments for various medical conditions. Its unique structure and properties make it a promising candidate for the development of novel therapeutic agents.
Used in Chemical Synthesis:
2-METHYLCARBAMOYLISONICOTINIC ACID ETHYL ESTER is used as a starting material or intermediate in the synthesis of other chemical compounds. Its unique structure and properties make it a valuable component in the production of a variety of chemical products.

InChI:InChI=1/C10H12N2O3/c1-3-15-10(14)7-4-5-12-8(6-7)9(13)11-2/h4-6H,3H2,1-2H3,(H,11,13)

Upstream product

• 123-39-7 N-Methylformamide 
• 1570-45-2 isonicotinic acid ethylester 

Downstream Products

• 332013-24-8 4-[({4-[(4-chlorophenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide 4-methylbenzenesulfonate 
• 332012-46-1 4-[({4-[(4-methoxyphenyl)amino]furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide 
• 332012-57-4 4-[({4-[(3-chlorophenyl)amino]-furo[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide 
• 332013-26-0 4-[({4-[(4-chlorophenyl)amino]furan[2,3-d]pyridazin-7-yl}oxy)methyl]-N-methyl-2-pyridinecarboxamide methanesulfonate 
• 332012-40-5 Telatinib 
• 1547120-68-2 C₂₄H₂₁Cl₂N₅O₂ 
• 1547120-64-8 C₂₃H₁₈Cl₃N₅O₂ 
• 1547120-63-7 C₂₃H₁₈Cl₂FN₅O₂ 
• 1547120-60-4 C₂₃H₁₉Cl₂N₅O₂ 
• 1547120-57-9 C₂₄H₁₉ClF₃N₅O₂ 
• 1547120-56-8 C₂₄H₁₈BrClF₃N₅O₂ 
• 1547120-51-3 C₂₄H₁₈Cl₂F₃N₅O₂ 
• 1547120-50-2 C₂₄H₁₈ClF₄N₅O₂ 
• 1547120-89-7 C₂₄H₁₉ClF₃N₅O₂ 

Relevant articles and documents

Design, synthesis and biological evaluation of indole derivatives as novel inhibitors targeting B-Raf kinase

A series of novel indole derivatives were designed and synthesized and their inhibitory activity against B-Raf and HepG2 cell were also described. Among them, compounds 7a and 7b exhibited excellent potency, which showed the potential for further research

SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY

Substituted pyridines and pyridazines having angiogenesis inhibiting activity and generalized structural formula (I) wherein the ring containing A, B, D, E, and L is phenyl or a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; R and R may be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermeability processes using these materials are also disclosed.

COMPOUNDS FOR TREATING PULMONARY HYPERTENSION

The present invention relates to pharmaceutical compositions and combinations for treating, preventing or managing pulmonary hypertension comprising small molecule heterocyclic pharmaceuticals, and more particularly, substituted pyridines and pyridazines optionally combined with at least one additional therapeutic agent.

Substituted pyridines and pyridazines with angiogenesis inhibiting activity

Substituted pyridazines having angiogenesis inhibiting activity and the generalized structural formula wherein the ring containing A, B, D, E, and L is phenyl or a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; R1and R2may be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermiability processes using these materials are also disclosed.